The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

A systematic literature review (2009–2016) of all non-pharmacological treatments, non-biological drugs (except targeted synthetic disease-modifying antirheumatic drugs (DMARDs)) and surgical therapies ...

In this publication, the authors report comparable clinical efficacy and safety profile between both drugs, but an apparent difference in immunogenicity, with ‘antidrug antibodies (ADAs)’ reported in ...